AXQ Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

AXQ Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,560	Closed	-$288K	–	794
2025 Q2	$288K	Buy	+4,560	New	+$279K	0.09%	370

Other funds holding RYTM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXQ Capital's RYTM Position: Q3 2025 in Review

AXQ Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2025, closing a stake of 4,560 shares — an estimated $288K sold.

AXQ Capital first reported a position in RYTM in Q2 2025 and held it in 1 quarter. The position peaked at $288K in Q2 2025. 264 funds tracked by Wall St. Rank hold RYTM as of Q3 2025.

AXQ Capital reported no remaining Rhythm Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
AXQ Capital sold 4,560 Rhythm Pharmaceuticals shares in Q3 2025, an estimated $288K.
AXQ Capital first reported a position in Rhythm Pharmaceuticals in Q2 2025 and held it in 1 quarter.
AXQ Capital's Rhythm Pharmaceuticals position peaked at $288K in Q2 2025.
264 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.